Rimegepant

Rimegepant
Clinical data
Trade names	Nurtec ODT
Other names	BHV-3000, BMS-927711
AHFS/Drugs.com	Monograph
MedlinePlus	a620031
License data	US DailyMed: Rimegepant;
Routes of; administration	By mouth
Drug class	calcitonin gene-related peptide receptor antagonist
ATC code	N02CD06 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate;
CAS Number	1289023-67-1;
PubChem CID	51049968;
DrugBank	DB12457;
ChemSpider	27289072;
UNII	997WVV895X;
KEGG	D10663; D10662;
ChEMBL	ChEMBL2178422;
CompTox Dashboard (EPA)	DTXSID70156003 ;
Chemical and physical data
Formula	C28H28F2N6O3
Molar mass	534.568 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;
	InChI InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1; Key:KRNAOFGYEFKHPB-ANJVHQHFSA-N;

Rimegepant, sold under the brand name Nurtec ODT, is a medication for the acute treatment of migraine with or without aura in adults and preventative treatment of episodic migraine in adults.^[1]^[2]

Taken by mouth to dissolve on or under the tongue,^[3] rimegepant takes effect within an hour and can provide relief from migraine headache for up to 48 hours. It works by blocking CGRP receptors.

In the United States, rimegepant was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021.^[2] It is produced and marketed by Biohaven Pharmaceuticals, based in New Haven, Connecticut.^[4]^[1] During March 2021, Nurtec ODT obtained approval from the United Arab emirates and Israel.^[5]^[6]^[7]

Mechanism of action[]

Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.^[8]

History[]

Originally discovered at Bristol-Myers Squibb,^[9] rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020.^[10] Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches.^[1]

References[]

^ ^a ^b ^c "Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Retrieved 19 March 2020. This article incorporates text from this source, which is in the public domain.
^ ^a ^b "Nurtec ODT Prescribing Information" (PDF). FDA.gov. U.S. Food and Drug Administration. June 2021.
^ "Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Retrieved 19 March 2020.
^ "Nurtec ODT: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 28 February 2020.
^ "Biohaven Pharma's (BHVN) NURTEC ODT Approved In Israel For Acute Treatment Of Migraine". StreetInsider.com. Retrieved 3 June 2021.
^ "Nurtec ODT: Treatment and Prevention of Migraine? And How to Get It". Migraine Again. 14 April 2021. Retrieved 3 June 2021.
^ "Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine". Biohaven Pharmaceuticals. Retrieved 3 June 2021.
^ Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–22. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968. S2CID 26523013.
^ "Rimegepant - Biohaven Pharmaceuticals Holding Company". Adis Insight. Springer Nature Switzerland AG.
^ "Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020 – via PR Newswire.

External links[]

"Rimegepant". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT03461757 for "Trial in Adult Subjects With Acute Migraines" at ClinicalTrials.gov

This analgesic-related article is a stub. You can help Wikipedia by .

[FDA_snapshot-1] "Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Retrieved 19 March 2020. This article incorporates text from this source, which is in the public domain.

[:0-2] "Nurtec ODT Prescribing Information" (PDF). FDA.gov. U.S. Food and Drug Administration. June 2021.

[Nurtec_ODT_FDA_label-3] "Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Retrieved 19 March 2020.

[4] "Nurtec ODT: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 28 February 2020.

[5] "Biohaven Pharma's (BHVN) NURTEC ODT Approved In Israel For Acute Treatment Of Migraine". StreetInsider.com. Retrieved 3 June 2021.

[6] "Nurtec ODT: Treatment and Prevention of Migraine? And How to Get It". Migraine Again. 14 April 2021. Retrieved 3 June 2021.

[7] "Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine". Biohaven Pharmaceuticals. Retrieved 3 June 2021.

[8] Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–22. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968. S2CID 26523013.

[9] "Rimegepant - Biohaven Pharmaceuticals Holding Company". Adis Insight. Springer Nature Switzerland AG.

[10] "Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020 – via PR Newswire.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]